drugset / Trial / NCT00392925

A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

NCT00392925

Phase 2 Completed 177 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.

Timeline

Start
2006-10
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metreleptin Protein / enzyme biologic 5 mg Subcutaneous
Subject Pramlintide Peptide 360 ug Subcutaneous

Indications